UK Drug Safety Update · July 21, 2026

Domperidone: new contraindication in patients with phaeochromocytoma due to risk of severe hypertension

Original title: Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension

Product information updated to add contraindication for confirmed or suspected phaeochromocytoma due to severe hypertension risk.

Low obligation Product class Pharmaceuticals UK Pharmacovigilance

The product information has been updated for all domperidone products, to include a contraindication for patients with confirmed or suspected phaeochromocytoma (a rare tumour of the adrenal gland), due to the risk of episode…

Read the official source ↗

Published by UK Drug Safety Update. HealthSignal links to the original document; the summary above is extracted from the source text.